Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182637 | 0.99 | ESR1 (0.40) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL27701283 | 0.88 | ESR1 (0.39) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL6169272 | 0.83 | SLC22A12 (0.38) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL6171090 | 0.82 | SLC22A12 (0.38) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL27701266 | 0.81 | CMKLR1 (0.38) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL682469 | 0.80 | ESR1 (0.38) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL683162 | 0.80 | ESR1 (0.40) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL3167730 | 0.80 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL6955349 | 0.80 | MAPT (0.42) | PDE4APDE4BPDE4CPDE4DESR1 | |
| SCHEMBL6796557 | 0.79 | PTGDR2 (0.47) | PDE4APDE4BPDE4CPDE4DESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1422849-A | indazole derivatives | PFIZER (US) | 2003-06-11 | — | — | CN | claimed |
| EP-2137162-B1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-08-01 | — | — | EP | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| CN-101657430-B | Organic compounds and uses thereof | NOVARTIS AG CH | 2013-05-01 | — | — | CN | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2137162-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-12-30 | — | — | EP | disclosed |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-09-03 | — | — | US | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-5958953-A | Substituted indazole derivatives | PFIZER INC (US) | 1999-09-28 | — | — | US | disclosed |
| CN-1223651-A | Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors | PFIZER (US) | 1999-07-21 | — | — | CN | disclosed |
| CN-1217714-A | Substituted indazole derivatives and their use as Phosphodiesterase (PDE) type IV and inhibitors of the production of Tumor Necrosis Factor (TNF) | PFIZER (US) | 1999-05-26 | — | — | CN | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999023076-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| EP-0912521-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0912558-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE (PDE) TYPE IV AND TUMOR NECROSIS FACTOR (TNF) INHIBITORS | PFIZER INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0816357-A1 | Substituted indazole derivatives | PFIZER INC. (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997049702-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHODIESTERASE (PDE) TYPE IV AND TUMOR NECROSIS FACTOR (TNF) INHIBITORS | PFIZER INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997042174-A1 | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885 |
| US-20100069368-A1 | Organic Compounds and Their Uses | SHH, GLI1, VHL | PDE4A 4105/4885PDE4B 3802/4885PDE4C 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.